Arbutus Biopharma (ABUS) Interest & Investment Income (2016 - 2025)
Arbutus Biopharma (ABUS) has disclosed Interest & Investment Income for 13 consecutive years, with $877000.0 as the latest value for Q4 2025.
- Quarterly Interest & Investment Income fell 40.1% to $877000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 38.22% year-over-year, with the annual reading at $4.1 million for FY2025, 38.22% down from the prior year.
- Interest & Investment Income hit $877000.0 in Q4 2025 for Arbutus Biopharma, down from $952000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.8 million in Q2 2024 to a low of $27000.0 in Q3 2021.
- Historically, Interest & Investment Income has averaged $933000.0 across 5 years, with a median of $997000.0 in 2025.
- Biggest five-year swings in Interest & Investment Income: plummeted 88.7% in 2021 and later skyrocketed 3043.33% in 2022.
- Year by year, Interest & Investment Income stood at $30000.0 in 2021, then soared by 3043.33% to $943000.0 in 2022, then soared by 55.36% to $1.5 million in 2023, then dropped by 0.07% to $1.5 million in 2024, then crashed by 40.1% to $877000.0 in 2025.
- Business Quant data shows Interest & Investment Income for ABUS at $877000.0 in Q4 2025, $952000.0 in Q3 2025, and $1.0 million in Q2 2025.